Although direct evidence of CD5 expression influencing BCL2 or MYC activation cannot be presented in the present study, the aggressive biologic behavior of CD5+ DLBCL might be related to the higher frequency of DE in this group. The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.